Schiff Nutrition International Names Scott K. Milsten Senior Vice President – General Counsel and Corporate Secretary
14 Julho 2011 - 8:05AM
Business Wire
Schiff Nutrition International, Inc. (NYSE:WNI) appointed Scott
K. Milsten Senior Vice President – General Counsel and Corporate
Secretary, effective July 12, 2011.
Tarang Amin, president and chief executive officer of Schiff
Nutrition, stated, “We are very pleased to welcome Scott to our
executive team. He brings extensive legal expertise as a General
Counsel with FDA, M&A and corporate governance experience.”
“Schiff has entered a new phase focusing on growth,” said Scott
Milsten. “I am excited to join the management team as we enhance
our position as a world-class nutritional supplements company.”
Milsten, 41, brings to Schiff six years of legal experience at
healthcare companies and nine years of additional law firm
experience. Most recently he was Senior Vice President, General
Counsel and Corporate Secretary at Celera Corporation where he was
responsible for the overall leadership of the legal function and
played a key role in the management team that sold the company to
Quest Diagnostics. Milsten also served as Deputy General Counsel,
Senior Director and Assistant Secretary at Gen-Probe Incorporated
from 2005 to 2007 and prior to that practiced corporate law at
Latham & Watkins LLP. Milsten holds a J.D. from the University
of Pennsylvania Law School and B.A. in English from Duke
University.
About Schiff Nutrition
Schiff Nutrition International, Inc. develops, manufactures,
markets and distributes branded and private label vitamins,
nutritional supplements and nutrition bars in the United States and
throughout the world. Schiff’s portfolio of well-known brands
includes Move Free®, Schiff® Vitamins, MegaRed®, Mega-D3™ and
Tiger's Milk®. To learn more about Schiff, please visit the web
site www.schiffnutrition.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that are based
on management’s beliefs and assumptions, current expectations,
estimates, and projections. These statements are subject to known
and unknown risks and uncertainties, certain of which are beyond
the company’s ability to control or predict, and therefore, actual
results may differ materially. Any forward-looking statements are
made pursuant to the Private Securities Litigation Reform Act of
1995 and, as such, speak only as of the date hereof. Schiff
Nutrition disclaims any obligation to update any forward-looking
statements whether as a result of new information, future events or
otherwise. You are cautioned not to place undue reliance on these
forward-looking statements.
Important factors that may cause actual results of Schiff
Nutrition to differ materially from those expressed or implied by
such forward-looking statements include, but are not limited to:
dependence on sales of our Move Free product and the joint care
category, dependence on sales of our MegaRed product, dependence on
individual customers, adverse publicity or consumer perception
regarding our nutritional supplements and/or their ingredients,
similar products distributed by other companies or the nutritional
supplement industry generally, the impact of competitive products
and pricing pressure (including expansion of private label
products), the inability to successfully bid on new and existing
private label business, the impact of raw material pricing,
availability and quality (particularly relating to joint care
products and ingredients from third-party suppliers outside the
United States, including China), claims that our products infringe
the intellectual property rights of others, the inability to
enforce or protect our intellectual property rights and proprietary
techniques against infringement, the inability to successfully
launch and maintain sales (especially in the joint care and omega-3
categories) outside of the United States while maintaining the
integrity of the products sold and complying with local
regulations, the inability to appropriately respond to changing
consumer preferences and demand for new products, the inability to
gain or maintain market distribution for new products or product
enhancements including products in the probiotic space, litigation
and government or administrative regulatory action in the United
States and internationally, including FDA enforcement and product
liability claims, the inability or increased cost to obtain
sufficient levels of product liability and general insurance, the
inability to comply with existing or new regulations, both in the
United States and abroad, and adverse actions regarding product
formulation, claims or advertising, product recalls or a
significant amount of product returns, dependence on a single
manufacturing facility and potential disruptions of our
manufacturing operations, the inability to find strategic
transaction opportunities or the inability to successfully
consummate or integrate a strategic transaction (including the
inability to successfully integrate the assets recently acquired
from Ganeden), the inability to maintain or attract key personnel,
interruptions to our information technology systems, control by our
principal stockholders, and other factors indicated from time to
time in the company’s SEC reports, copies of which are available
upon request from the company’s investor relations department or
may be obtained at the SEC's web site (www.sec.gov). These risks and uncertainties should
be carefully considered before making an investment decision with
respect to shares of our common stock.
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Schiff Nutrit (NYSE:WNI)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024